Trial reportEndoscopy2016
Multimodal endoscope can quantify wide-field fluorescence detection of Barrett's neoplasia.
Trial report in Endoscopy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01630798 (A Phase 1B In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1B In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Fluorescence Imaging of Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Highlighting the Undetectable - Fluorescence Molecular Imaging in Gastrointestinal Endoscopy.Molecular imaging and biology · 2023Review
- Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.Diagnostics (Basel, Switzerland) · 2022Review
- Today's Mistakes and Tomorrow's Wisdom in Endoscopic Imaging of Barrett's Esophagus.Visceral medicine · 2022Review
- Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.European journal of nuclear medicine and molecular imaging · 2022Article
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
- Review
- Membrane Bound Peroxiredoxin-1 Serves as a Biomarker forAntioxidants & redox signaling · 2022Article
- Is Malignant Potential of Barrett's Esophagus Predictable by Endoscopy Findings?Life (Basel, Switzerland) · 2020Review
- Use of Fluorescent Dyes in Endoscopy and Diagnostic Investigation.Visceral medicine · 2020Review
- Multiplexed Imaging Strategy to Distinguish Indeterminant Biliary Strictures: AnWorld journal of gastroenterology, hepatology and endoscopy · 2020Article
- Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet.Scientific reports · 2019Article
- Environmentally compatible bioconjugated gold nanoparticles as efficient contrast agents for inflammation-induced cancer imaging.Nanoscale research letters · 2019Article
- Calibration of fluorescence imaging for tumor surgical margin delineation: multistep registration of fluorescence and histological images.Journal of medical imaging (Bellingham, Wash.) · 2019Article
- Article
- Dual-modal in vivo fluorescence and photoacoustic imaging using a heterodimeric peptide.Chemical communications (Cambridge, England) · 2018Article
- Bimodal reflectance and fluorescence multispectral endoscopy based on spectrally resolving detector arrays.Journal of biomedical optics · 2018Article
- Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications.Contrast media & molecular imaging · 2018Review
- Identification and validation of FGFR2 peptide for detection of early Barrett's neoplasia.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND STUDY
aimsTo demonstrate the clinical use of a multimodal endoscope with a targeted fluorescently labeled peptide for quantitative detection of Barrett's neoplasia. PATIENTS AND
methodsWe studied 50 patients with Barrett's esophagus using a prototype multimodal endoscope with a fluorescently labeled peptide. Co-registered fluorescence and reflectance images were converted to ratios to correct for differences in distance and geometry over the image field of view. The ratio images were segmented using a unique threshold that maximized the variance between high and low intensities to localize regions of high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC).
resultsEarly neoplasia (HGD and EAC) was identified with 94 % specificity and 96 % positive predictive value at a threshold of 1.49. The mean results for HGD and EAC were significantly greater than those for squamous/Barrett's esophagus and low grade dysplasia by one-way analysis of variance (ANOVA). The receiver operator characteristic curve for detection of early neoplasia had an area under the curve of 0.884. No adverse events associated with the endoscope or peptide were found.
conclusionA multimodal endoscope can quantify fluorescence images from targeted peptides to localize early Barrett's neoplasia. (ClinicalTrials.gov number NCT01630798.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.